Landiolol hydrochloride is an ultra-short-acting beta-blocker with a favorable pharmacokinetic profile and safety in patients with tachyarrhythmias.
Landiolol may aid acute tachyarrhythmia management; leaves open comparative outcome trials.
Landiolol hydrochloride has a shorter elimination half-life than any other beta-blocker, and it can be administered safely to patients with various tachyarrhythmias.
No takes yet. Share an insight, caveat, or question.
Hirotsugu Atarashi (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: